Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |20 March 2007

What Is the Best Treatment Plan for Early Rheumatoid Arthritis? Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled “Comparison of Treatment Strategies in Early Rheumatoid Arthritis. A Randomized Trial.” It is in the 20 March 2007 issue of Annals of Internal Medicine (volume 146, pages 406-415). The authors are Y.P.M. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, C.F. Allaart, D. van Zeben, P.J.S.M. Kerstens, J.M.W. Hazes, A.H. Zwinderman, A.J. Peeters, J.M. de Jonge-Bok, C. Mallée, W.M. de Beus, P.B.J. de Sonnaville, J.A.P.M. Ewals, F.C. Breedveld, and B.A.C. Dijkmans.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Rheumatoid arthritis causes inflammation of the joints and often produces pain, deformity, and disability. The cause of the disease is unknown, but doctors know that the disease produces inflammation of the joint surfaces where the cartilage-covered ends of the bones rub against each another as the joint bends. Prolonged inflammation damages the joint and produces permanent changes in its structure. Doctors have used many medications to decrease joint inflammation and have been successful in managing the disease. Although some of that success has been achieved by using progressively more powerful disease-modifying antirheumatic drugs and medications that control inflammation, success also seems to be due in part to the way that doctors use combinations of these medications. To determine the best ways of treating rheumatoid arthritis early in the course of the disease, researchers began a study (known as the BeSt study) of patients who were treated with 1 of 4 plans. Group 1 received a single drug that was changed to another powerful drug every 3 months until the disease was controlled. Group 2 also started therapy with a single drug that was progressively stepped-up to combination therapy until control was achieved. Group 3 received combination therapy and high-dose prednisone until control was achieved. Group 4 received combination therapy and a new drug (infliximab) that blocks the body's ability to develop inflammation. In all groups, therapy was adjusted every 3 months until there was adequate disease control. Medication doses were reduced in all groups once the disease was controlled. Results during the first year showed that although all groups improved, groups 3 and 4 had more rapid control of the disease and had less damage to the joints than did groups 1 and 2.

Why did the researchers do this particular study?

To find out whether improvement could be maintained during the second year of treatment and what medication adjustments needed to be made for each group.

Who was studied?

508 patients who participated in the first year of the BeSt study.

How was the study done?

Patients were evaluated every 3 months by using a standardized scoring system known as the disease activity score. Evaluation of disease activity was done by a nurse who did not know the patient's treatment group. Changes in medication were made by doctors on the basis of the disease activity score and the group to which the patient was assigned.

What did the researchers find?

Improvement was maintained in all groups during the second year. By the end of the study, about one third of patients in groups 1, 2, and 3 and about half of the patients in group 4 had reached disease control with their first medication and needed only 1 drug. Eventually, all groups had clinical improvement.

What were the limitations of the study?

The patients and the physicians knew which treatment the patients were receiving.

What are the implications of the study?

Modern drug therapy can effectively control rheumatoid arthritis. Combination therapy produces more rapid disease control and probably limits joint damage more effectively than does therapy with a single drug.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

What Is the Best Treatment Plan for Early Rheumatoid Arthritis?. Ann Intern Med. 2007;146:I–63. doi: https://doi.org/10.7326/0003-4819-146-6-200703200-00002

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2007;146(6):I-63.

DOI: 10.7326/0003-4819-146-6-200703200-00002

©
2007 American College of Physicians
0 Citations

See Also

Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial
View MoreView Less

Related Articles

A Student Reflection on Doctoring With Confidence: Mind the Gap
Annals of Internal Medicine; 169 (8): 564-565
Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study
Annals of Internal Medicine; 169 (5): 291-299
In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms
Annals of Internal Medicine; 168 (4): JC23
Erosive Rheumatoid Arthritis After Bilateral Hand Transplantation
Annals of Internal Medicine; 167 (3): 216-218
View MoreView Less

Journal Club

In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms
Annals of Internal Medicine; 168 (4): JC23
Patients with new-onset rheumatoid arthritis had increased risk for ischemic and nonischemic heart failure
Annals of Internal Medicine; 167 (2): JC8
Review: In rheumatoid arthritis, TNF-α inhibitors do not differ from placebo or DMARDs for all-cause mortality
Annals of Internal Medicine; 164 (4): JC20
Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes
Annals of Internal Medicine; 162 (12): JC9
View MoreView Less

Related Point of Care

Rheumatoid Arthritis
Annals of Internal Medicine; 153 (1): ITC1-1
View MoreView Less

Related Topics

Rheumatoid Arthritis
Rheumatology

Rheumatoid Arthritis, Rheumatology.

PubMed Articles

Traditional uses, phytochemistry, and pharmacology of Persicaria orientalis (L.) Spach - A review.
J Ethnopharmacol 2019.
Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity.
Biochem Pharmacol 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×